Elevated CA 19-9 levels in mature cystic teratoma of the ovary

International Journal of Biological Markers

Volumn 24, Issue 1, 2009, Pages 52-56

  Kyung, Min Sun ^a   Choi, Joong Sub ^b   Hong, Seung Hwa ^c   Kim, Hak Soon ^c  

^a Hallym University College of Medicine   (South Korea)

^b School of Medicine   (South Korea)

^c Chungbuk National University Hospital   (South Korea)

Author keywords

CA 125; CA 19 9; Ovary; Teratoma; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTECTOMY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LAPAROSCOPY; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY TERATOMA; PROTEIN BLOOD LEVEL; SALPINGOOOPHORECTOMY; TORSION; TUMOR VOLUME;

EID: 67649961607     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.3363     Document Type: Article

References (25)

1. Al-Fozan H, Glassman J, Caspi B, Appelman Z, Tulandi T. Lateral distribution of ovarian dermoid cyst. J Am Assoc Gynecol Laparosc 2003; 10: 489-90.
2. Ayhan A, Bukulmez O, Genc C, Karamursel BS, Ayhan A. Mature cystic teratomas of the ovary: case series from one institution over 34 years. Eur J Obstet Gynecol Reprod Biol 2000; 88: 153-7.
3. Comerci JT Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol 1994; 84: 22-8.
4. Peterson WF, Prevost EC, Edmunds FT, Hundley JM Jr, Morris FK. Benign cystic teratomas of the ovary; a clinico-statistical study of 1,007 cases with a review of the literature. Am J Obstet Gynecol 1955; 70: 368-82.
5. Patel MD, Feldstein VA, Lipson SD, Chen DC, Filly RA. Cystic teratomas of the ovary: diagnostic value of sonography. AJR Am J Roentgenol 1998; 171: 1061-5.
6. Outwater EK, Siegelman ES, Hunt JL. Ovarian teratomas: tumor types and imaging characteristics. Radiographics 2001; 21: 475-90.
7. Atabekoglu C, Bozaci EA, Tezcan S. Elevated carbohydrate antigen 19-9 in a dermoid cyst. Int J Gynaecol Obstet 2005; 91: 262-3.
8. Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Hasimi A. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer 2006; 16: 189-93.
9. Ito K. CA19-9 in mature cystic teratoma. Tohoku J Exp Med 1994; 172: 133-8.
10. Kawai M, Kano T, Kikkawa F, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol 1992; 45: 248-53.
11. Nanayakkara S, Ali S, Gilmour K. Increased serum carcinomic antigen 19-9 (CA 19-9) in a dermoid cyst. J Obstet Gynaecol 2007; 27: 96-7.
12. Dos Santos L, Mok E, Iasonos A, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol 2007; 105: 321-4.
13. Tangjitgamol S, Manusirivithaya S, Sheanakul C, Leelahakorn S, Thawaramara T, Jesadapatarakul S. Squamous cell carcinoma arising from dermoid cyst: Case reports and review of literature. Int J Gynecol Cancer 2003; 13: 558-63.
14. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005; 18 (Suppl 2): S61-79.
15. Kikkawa F, Nawa A, Tamakoshi K, et al. Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary. Cancer 1998; 82: 2249-55.
16. Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991; 78: 70-6.
17. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003; 21: 200s-5s.
18. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-7.
19. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998; 13: 179-87.
20. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988; 72: 23-7.
21. Arakawa Y, Ariga H, Kano M, Matsuo Y, Honda T, Morita K. Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers. Jpn J Med 1985; 24: 121-30.
22. von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996; 16: 2325-31.
23. Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer 1996; 78: 57-62.
24. Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol 1981; 58: 497-504.
25. Pantoja E, Noy MA, Axtmayer RW, et al. Ovarian dermoids and their complications. Comprehensive historical review. Obstet Gynecol Surv 1975; 30: 1-20.